drugset / Trial / NCT00191919

A Randomized Double Blind Study Evaluating Duloxetine in Outpatients With MDD and Pain

NCT00191919

Phase 3 Completed 310 enrolled Eli Lilly and Company Boehringer Ingelheim · collab
RandomizedParallel-groupDouble-blindTreatment

Summary

To determine the efficacy of Duloxetine vs. placebo on pain as determined by change in the Brief Pain Inventory (BPI) from baseline over 8 weeks of treatment

Timeline

Start
2005-05
Primary completion
Completion
2006-05

Drugs

EvaluationDrugModalityDoseRoute
Subject Duloxetine Small molecule 60 mg